IS4023A - Hliðstæð aðferð til framleiðslu á nýjum N-Aryl ogN-Heteroarylurea afleiðum sem vinna gegn acyl kóensími A: kólesteról acyl transferasa (ACAT) - Google Patents

Hliðstæð aðferð til framleiðslu á nýjum N-Aryl ogN-Heteroarylurea afleiðum sem vinna gegn acyl kóensími A: kólesteról acyl transferasa (ACAT)

Info

Publication number
IS4023A
IS4023A IS4023A IS4023A IS4023A IS 4023 A IS4023 A IS 4023A IS 4023 A IS4023 A IS 4023A IS 4023 A IS4023 A IS 4023A IS 4023 A IS4023 A IS 4023A
Authority
IS
Iceland
Prior art keywords
acat
aryl
new
production
act against
Prior art date
Application number
IS4023A
Other languages
English (en)
Inventor
S. Hamanaka Ernest
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of IS4023A publication Critical patent/IS4023A/is

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/75Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38Nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/58Two sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/58Radicals substituted by nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/66Nitrogen atoms not forming part of a nitro radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Quinoline Compounds (AREA)
IS4023A 1992-05-28 1993-05-24 Hliðstæð aðferð til framleiðslu á nýjum N-Aryl ogN-Heteroarylurea afleiðum sem vinna gegn acyl kóensími A: kólesteról acyl transferasa (ACAT) IS4023A (is)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US89005092A 1992-05-28 1992-05-28

Publications (1)

Publication Number Publication Date
IS4023A true IS4023A (is) 1993-11-29

Family

ID=25396173

Family Applications (1)

Application Number Title Priority Date Filing Date
IS4023A IS4023A (is) 1992-05-28 1993-05-24 Hliðstæð aðferð til framleiðslu á nýjum N-Aryl ogN-Heteroarylurea afleiðum sem vinna gegn acyl kóensími A: kólesteról acyl transferasa (ACAT)

Country Status (23)

Country Link
US (1) US6001860A (is)
EP (1) EP0642498A1 (is)
JP (1) JPH07503737A (is)
KR (1) KR950701621A (is)
CN (1) CN1080919A (is)
AU (1) AU4028393A (is)
BG (1) BG99188A (is)
BR (1) BR9306421A (is)
CA (1) CA2134359C (is)
FI (1) FI932423L (is)
HR (1) HRP930931A2 (is)
HU (1) HUT64303A (is)
IL (1) IL105756A0 (is)
IS (1) IS4023A (is)
MA (1) MA22896A1 (is)
MX (1) MX9303100A (is)
OA (1) OA10114A (is)
PL (1) PL299082A1 (is)
RU (1) RU94046149A (is)
SK (1) SK142694A3 (is)
UY (1) UY23589A1 (is)
WO (1) WO1993024458A1 (is)
YU (1) YU37193A (is)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4028393A (en) * 1992-05-28 1993-12-30 Pfizer Inc. New (N)-aryl and (N)-heteroarylurea derivatives as inhibitors of acyl coenzyme a:cholesterol acyl transferase (ACAT)
NZ250916A (en) * 1993-02-27 1995-08-28 Nihon Nohyaku Co Ltd N-heteroaryl-n'-phenylureas, their use as acat inhibitors
IL109568A0 (en) * 1993-05-19 1994-08-26 Fujisawa Pharmaceutical Co Urea derivatives, pharmaceutical compositions containing the same and processes for the preparation thereof
ES2076865B1 (es) * 1993-07-05 1996-08-01 Pfizer Nuevos derivados de n-aril- y n-heteroaril-urea como inhibidores de acil-coenzima a: colesterol acil transferasa (acat).
NZ264063A (en) * 1993-08-13 1995-11-27 Nihon Nohyaku Co Ltd N-(2-phenylpyrid-3-yl)- and n-(4-phenylpyrimidin-5-yl)-n'-phenylurea derivatives and pharmaceutical compositions
DE4401893A1 (de) * 1994-01-24 1995-07-27 Bayer Ag Substituierte Arylharnstoffe
US6133326A (en) * 1994-08-31 2000-10-17 Pfizer Inc Compositions and methods for decreasing sebum production
KR970706242A (ko) * 1994-10-04 1997-11-03 후지야마 아키라 우레아 유도체 및 ACAT-억제제로서 그의 용도(Urea derivatives and their use as ACAT-inhibitors)
HUP9602538A3 (en) * 1995-09-18 1997-08-28 Sankyo Co New urea and amide derivatives having acat inhibitory activity, their preparation and their use
TR199900364T2 (xx) 1996-08-22 1999-05-21 Warner-Lambert Company Peptid olmayan bombesin resept�r antagonistleri.
US6187799B1 (en) 1997-05-23 2001-02-13 Onyx Pharmaceuticals Inhibition of raf kinase activity using aryl ureas
EP1028953A1 (en) * 1997-11-03 2000-08-23 Boehringer Ingelheim Pharmaceuticals Inc. Aromatic heterocyclic compounds as anti-inflammatory agents
EP1473292A1 (en) * 1997-11-03 2004-11-03 Boehringer Ingelheim Pharmaceuticals, Inc. Aromatic heterocyclic compounds as anti-inflammatory agents
US7329670B1 (en) 1997-12-22 2008-02-12 Bayer Pharmaceuticals Corporation Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas
US7517880B2 (en) 1997-12-22 2009-04-14 Bayer Pharmaceuticals Corporation Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
EP1158985B1 (en) 1999-01-13 2011-12-28 Bayer HealthCare LLC OMEGA-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS
EP1140840B1 (en) 1999-01-13 2006-03-22 Bayer Pharmaceuticals Corp. -g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
ME00275B (me) 1999-01-13 2011-02-10 Bayer Corp ω-KARBOKSIARIL SUPSTITUISANI DIFENIL KARBAMIDI KAO INHIBITORI RAF KINAZE
UA73492C2 (en) 1999-01-19 2005-08-15 Aromatic heterocyclic compounds as antiinflammatory agents
CA2360934A1 (en) 1999-02-22 2000-08-31 Lin-Hua Zhang Polycyclo heterocyclic derivatives as antiinflammatory agents
ATE278674T1 (de) 1999-03-12 2004-10-15 Boehringer Ingelheim Pharma Heterocyklischer harnstoff und verwandte verbindungen als entzündungshemmende mittel
JP2002539206A (ja) 1999-03-12 2002-11-19 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド 抗炎症剤としての芳香族複素環化合物
CA2374737C (en) 1999-07-09 2008-02-12 Boehringer Ingelheim Pharmaceuticals, Inc. Novel process for synthesis of heteroaryl-substituted urea compounds
EP1232150B1 (en) 1999-11-16 2007-10-10 Boehringer Ingelheim Pharmaceuticals Inc. Urea derivatives as anti-inflammatory agents
US6525046B1 (en) 2000-01-18 2003-02-25 Boehringer Ingelheim Pharmaceuticals, Inc. Aromatic heterocyclic compounds as antiinflammatory agents
EP1263421B1 (en) 2000-02-02 2005-05-18 Warner-Lambert Company LLC The dual inhibitor of cholesteryl ester and wax ester synthesis avasimibe for treating sebaceous gland disorders
US6608052B2 (en) 2000-02-16 2003-08-19 Boehringer Ingelheim Pharmaceuticals, Inc. Compounds useful as anti-inflammatory agents
US7235576B1 (en) 2001-01-12 2007-06-26 Bayer Pharmaceuticals Corporation Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US7371763B2 (en) 2001-04-20 2008-05-13 Bayer Pharmaceuticals Corporation Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
JP2004530690A (ja) 2001-05-16 2004-10-07 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド 抗炎症性薬剤として有用なジアリールウレア誘導体
EP1395561A1 (en) 2001-05-25 2004-03-10 Boehringer Ingelheim Pharmaceuticals Inc. Carbamate and oxamide compounds as inhibitors of cytokine production
PL370989A1 (en) * 2001-12-21 2005-06-13 Novo Nordisk A/S Amide derivatives as gk activators
ATE529406T1 (de) 2002-02-11 2011-11-15 Bayer Healthcare Llc Aryl-harnstoffe als kinase inhibitoren
SI1478358T1 (sl) 2002-02-11 2013-09-30 Bayer Healthcare Llc Sorafenib tozilat za zdravljenje bolezni, značilnih po abnormalni angiogenezi
EP1480973B1 (en) 2002-02-25 2008-02-13 Boehringer Ingelheim Pharmaceuticals Inc. 1,4-disubstituted benzofused cycloalkyl urea compounds useful in treating cytokine mediated diseases
GB0206876D0 (en) 2002-03-22 2002-05-01 Merck Sharp & Dohme Therapeutic agents
AU2003243921B2 (en) 2002-06-27 2009-05-07 Novo Nordisk A/S Aryl carbonyl derivatives as therapeutic agents
ATE552236T1 (de) * 2003-01-14 2012-04-15 Cytokinetics Inc Verbindungen, zusammensetzungen und verfahren zur behandlung von herzinsuffizienz
US7375126B2 (en) * 2003-06-12 2008-05-20 Abbott Laboratories Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
US7015233B2 (en) * 2003-06-12 2006-03-21 Abbott Laboratories Fused compounds that inhibit vanilloid subtype 1 (VR1) receptor
EP1663978B1 (en) 2003-07-23 2007-11-28 Bayer Pharmaceuticals Corporation Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
BRPI0506662B8 (pt) * 2004-01-06 2021-05-25 Novo Nordisk As compostos ativadores de glucoquinase
US7262318B2 (en) * 2004-03-10 2007-08-28 Pfizer, Inc. Substituted heteroaryl- and phenylsulfamoyl compounds
ES2522579T3 (es) 2004-06-17 2014-11-17 Cytokinetics, Inc. Compuestos, composiciones y métodos
US7176222B2 (en) 2004-07-27 2007-02-13 Cytokinetics, Inc. Syntheses of ureas
JP2009500377A (ja) * 2005-07-08 2009-01-08 ノボ・ノルデイスク・エー/エス ジシクロアルキルウレア型グルコキナーゼ活性化剤
EP1904438B1 (en) * 2005-07-08 2012-02-29 Novo Nordisk A/S Dicycloalkylcarbamoyl ureas as glucokinase activators
EP1904467B1 (en) 2005-07-14 2013-05-01 Novo Nordisk A/S Urea glucokinase activators
US7538223B2 (en) * 2005-08-04 2009-05-26 Cytokinetics, Inc. Compounds, compositions and methods
US20070208000A1 (en) * 2005-12-15 2007-09-06 Morgan Bradley P Certain chemical entities, compositions and methods
EP1959947A2 (en) * 2005-12-15 2008-08-27 Cytokinetics, Inc. Certain chemical entities, compositions and methods
ES2419007T3 (es) * 2005-12-15 2013-08-19 Cytokinetics, Inc. Ciertas entidades químicas, composiciones y procedimientos
US7825120B2 (en) * 2005-12-15 2010-11-02 Cytokinetics, Inc. Certain substituted ((piperazin-1-ylmethyl)benzyl)ureas
WO2007078815A2 (en) * 2005-12-16 2007-07-12 Cytokinetics, Inc. Certain chemical entities, compositions, and methods
WO2007078839A2 (en) * 2005-12-19 2007-07-12 Cytokinetics, Inc. Compounds, compositions and methods
JP5015496B2 (ja) * 2006-06-01 2012-08-29 ルネサスエレクトロニクス株式会社 固体撮像装置、撮像方法および撮像システム
CA2661898A1 (en) * 2006-08-25 2008-02-28 Abbott Laboratories Indazole derivatives that inhibit trpv1 and uses thereof
CA2672196A1 (en) 2006-12-20 2008-07-03 Abbott Laboratories Antagonists of the trpv1 receptor and uses thereof
EP2118083A1 (en) * 2007-01-09 2009-11-18 Novo Nordisk A/S Urea glucokinase activators
JP5226008B2 (ja) 2007-01-11 2013-07-03 ノボ・ノルデイスク・エー/エス ウレアグルコキナーゼアクチベーター
PE20091041A1 (es) * 2007-10-19 2009-08-22 Abbott Gmbh & Co Kg Producto de dispersion solida que contiene un compuesto a base de n-aril urea
WO2009100176A2 (en) * 2008-02-07 2009-08-13 Abbott Laboratories Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor
EP2489660A1 (en) * 2008-03-20 2012-08-22 Abbott Laboratories Methods for making central nervous system agents that are TRPV1 antagonists
CN103172543B (zh) * 2011-12-21 2016-02-10 中国科学院上海药物研究所 一种脲类化合物、制备方法及其用途
TWI539385B (zh) 2015-01-28 2016-06-21 金佶科技股份有限公司 光動能指紋辨識模組
CN112040945A (zh) 2018-06-12 2020-12-04 Vtv治疗有限责任公司 葡萄糖激酶激活剂与胰岛素或胰岛素类似物组合的治疗用途
US12391658B2 (en) 2020-02-18 2025-08-19 Vtv Therapeutics Llc Sulfoxide and sulfone glucokinase activators and methods of use thereof
US20240300939A1 (en) 2021-06-14 2024-09-12 Scorpion Therapeutics, Inc. Urea derivatives which can be used to treat cancer

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3426031A (en) * 1967-01-19 1969-02-04 Dow Chemical Co 3,5,6 - trichloro - 4 - (3 - (alpha,alpha,alpha,alpha',alpha',alpha'-hexafluoro - 3,5 - xylyl)ureido) picolinic acid and the corresponding amide derivative
US4623662A (en) * 1985-05-23 1986-11-18 American Cyanamid Company Antiatherosclerotic ureas and thioureas
US4751026A (en) * 1986-03-24 1988-06-14 Warner-Lambert Company Substituted anilides of oleic, linoleic, or linolenic acid as inhibitors of acyl-coa:cholesterol acyltransferase
US4722927A (en) * 1986-04-28 1988-02-02 Warner-Lambert Company Pyrimidine amides of oleic or linoleic acid, composition containing them and their use as inhibitors of acyl-CoA cholesterol acyltransferase
JPS6323848A (ja) * 1986-07-11 1988-02-01 ワ−ナ−−ランバ−ト・コンパニ− Ω−(置換フエニルオキシ)−アルカン酸のアリ−ル−およびアラルキルアミド
US4743605A (en) * 1987-02-24 1988-05-10 Warner-Lambert Company Saturated fatty acid amides as inhibitors of acyl-coa:cholesterol acyltransferase
US4716175A (en) * 1987-02-24 1987-12-29 Warner-Lambert Company Saturated fatty acid amides as inhibitors of acyl-CoA:cholesterol acyltransferase
IE61716B1 (en) * 1987-06-02 1994-11-30 Warner Lambert Co Antihyperlipidemic and antiatherosclerotic urea compounds
US5015644A (en) * 1987-06-02 1991-05-14 Warner-Lambert Company Antihyperlipidemic and antiatherosclerotic urea and carbamate compounds
ATE61574T1 (de) * 1987-07-02 1991-03-15 Warner Lambert Co N-((2,6-disubstituierte)-phenyl>-harnstoff und - carbamat-inhibitoren der acyl-coenzym a:cholesterol-acyltransferase.
US4868210A (en) * 1988-03-30 1989-09-19 Warner-Lambert Company Antihyperlipidemic and antiatherosclerotic compounds and compositions
US5116848A (en) * 1988-03-30 1992-05-26 Warner-Lambert Company N-(((2,6-disubstituted)phenyl)-n-diarylalkyl)ureas as antihyperlipidemic and antiatherosclerotic agents
US5155127A (en) * 1989-02-09 1992-10-13 Warner-Lambert Company N-(substituted aryl)-n'-(substituted alkoxy)-ureas and thioureas as antihypercholesterolemic and antiatherosclerotic agents
US4994465A (en) * 1989-02-17 1991-02-19 Warner-Lambert Company Antihyperlipidemic and antiatherosclerotic trisubstituted urea compounds
PT93158A (pt) * 1989-02-17 1990-08-31 Warner Lambert Co Processo para a preparacao de compostos de ureia trissubstituidos e de composicoes farmaceuticas que os contem
AU632809B2 (en) * 1989-05-25 1993-01-14 Takeda Chemical Industries Ltd. Benzocycloalkane benzopyran and benzothiopyran urea derivatives and production thereof
ZA903906B (en) * 1989-05-25 1992-02-26 Takeda Chemical Industries Ltd Benzocycloalkane derivatives and production thereof
AU629376B2 (en) * 1989-08-04 1992-10-01 Mitsubishi Chemical Corporation 1-phenylalkyl-3-phenylurea derivatives
WO1991004027A1 (en) * 1989-09-15 1991-04-04 Pfizer Inc. New n-aryl and n-heteroarylamide and urea derivatives as inhibitors of acyl coenzyme a: cholesterol acyl transferase (acat)
TW205037B (is) * 1989-10-06 1993-05-01 Takeda Pharm Industry Co Ltd
JPH05310678A (ja) * 1990-01-22 1993-11-22 Mitsubishi Kasei Corp 1−フェニルアルキル−3−フェニル尿素誘導体
ATE115558T1 (de) * 1990-03-12 1994-12-15 Yamanouchi Pharma Co Ltd Harnstoffderivate, deren herstellung sowie diese enthaltende pharmazeutische zusammensetzungen.
AU7440691A (en) * 1990-03-12 1991-10-10 Yamanouchi Pharmaceutical Co., Ltd. Monourea derivative and its salt
US5668136A (en) * 1990-09-25 1997-09-16 Eisai Co., Ltd. Trisubstituted benzene derivatives, composition and methods of treatment
FR2674522B1 (fr) * 1991-03-26 1993-07-16 Lipha Nouveaux derives de l'indole, procedes de preparation et medicaments les contenant.
IL101785A0 (en) * 1991-05-10 1992-12-30 Fujisawa Pharmaceutical Co Urea derivatives,processes for the preparation thereof and pharmaceutical compositions containing the same
AU4028393A (en) * 1992-05-28 1993-12-30 Pfizer Inc. New (N)-aryl and (N)-heteroarylurea derivatives as inhibitors of acyl coenzyme a:cholesterol acyl transferase (ACAT)

Also Published As

Publication number Publication date
CA2134359A1 (en) 1993-12-09
FI932423A7 (fi) 1993-11-29
KR950701621A (ko) 1995-04-28
WO1993024458A1 (en) 1993-12-09
EP0642498A1 (en) 1995-03-15
SK142694A3 (en) 1995-06-07
CN1080919A (zh) 1994-01-19
HUT64303A (en) 1993-12-28
OA10114A (en) 1996-12-18
US6001860A (en) 1999-12-14
PL299082A1 (en) 1994-04-05
FI932423L (fi) 1993-11-29
AU4028393A (en) 1993-12-30
MA22896A1 (fr) 1993-12-31
FI932423A0 (fi) 1993-05-27
MX9303100A (es) 1994-06-30
UY23589A1 (es) 1993-11-15
YU37193A (sh) 1997-07-31
BG99188A (bg) 1995-07-28
HRP930931A2 (en) 1997-06-30
IL105756A0 (en) 1993-09-22
JPH07503737A (ja) 1995-04-20
BR9306421A (pt) 1998-09-15
CA2134359C (en) 1997-07-01
RU94046149A (ru) 1996-11-27
HU9301552D0 (en) 1993-09-28

Similar Documents

Publication Publication Date Title
IS4023A (is) Hliðstæð aðferð til framleiðslu á nýjum N-Aryl ogN-Heteroarylurea afleiðum sem vinna gegn acyl kóensími A: kólesteról acyl transferasa (ACAT)
IS3970A (is) Hliðstæð aðferð til framleiðslu á 1,5-benzódíazepín afleiðum
ZA9710038B (en) Method for the production of levulinic acid and its derivatives
ZA985594B (en) Plant and process for the production of metal melts
AU617818B2 (en) A corrugated pipe, a method of forming the corrugated pipe and an apparatus for manufacturing the same
FI943841L (fi) Liitin laipoitetuille putkille, prosessi laippojen liittämiseksi ja liittimen käyttö
GB9511118D0 (en) A turbomachine aerofoil and a method of production
IS3919A (is) Hliðstæð aðferð til framleiðslu á heteróarýl amínum sem mynda nýja asetýlkólínesterasatálma
HUP9702042A3 (en) Use of 1,1,2-triphenil but-1-ene derivatives for the production of medicaments against atherosclerosis
EP0913496A4 (en) PART COATED BY HIGH-TEMPERATURE SPRAYING AND METHOD FOR THE PRODUCTION THEREOF
GB2240490B (en) A corrosion-inhibiting coating,and method of forming same
PT770687E (pt) Processo para a producao de nicotinamida
PL306730A1 (en) Derivatives of alpha-pyrimidinylacrylic acid, method of obtaining them and their applications
NO304949B1 (no) Nye glukose- og soforoselipider, en fremgangsmÕte for fremstilling derav og anvendelse av lipidene
HU9501041D0 (en) Peptide-boronic acid derivatives, process for producing them and pharmaceutical application thereof
PL312693A1 (en) Oxathiolanes, method of their production and pharmaceutical compounds containing them
SI0811689T1 (en) Process for the production of clavulanic acid and/or salts thereof
PL320536A1 (en) Derivatives of 3-benzoylopyridine, their production and application as herbicides
ZA96518B (en) Method and apparatus for tacking intended for the assembly of a crane girder casing
HUP9900170A2 (hu) Trovafloxacin ikerionos alakjai, eljárás előállításukra és ezeket tartalmazó gyógyszerkészítmények
GB2215269B (en) A method and an arrangement for joining the ends of a band-shaped product
IS4707A (is) Aðferð til framleiðslu á díoxóazabísýklóhexönum
HUT36666A (en) Herbicides consisting of - as agents - 2-aril-2-/halogen-alkyl/-oxirane derivatives and process for production of the agents
NO985716L (no) FremgangsmÕte for fremstilling av vannoppl÷selige derivater av kinoner
HUP0003630A2 (en) Method for the production of 2,6-dichloro-5-fluoronicotinonitrile and the chemical compound 3-cyano-2-hydroxy-5-fluoropyride-6-one-monosodium salt and its tautomers